{"id":483684,"date":"2025-06-26T00:00:00","date_gmt":"2025-06-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0031-2025-biopharma-ulcerative-colitis-access-reimbursement-access-reimbursement-ulcerative-colitis-us\/"},"modified":"2026-04-29T23:10:57","modified_gmt":"2026-04-29T23:10:57","slug":"acreim0031-2025-biopharma-ulcerative-colitis-access-reimbursement-access-reimbursement-ulcerative-colitis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0031-2025-biopharma-ulcerative-colitis-access-reimbursement-access-reimbursement-ulcerative-colitis-us\/","title":{"rendered":"Ulcerative Colitis &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Ulcerative Colitis (US)"},"content":{"rendered":"<p>TNF-alpha inhibitors (e.g., Johnson &#038; Johnson Innovative Medicine\u2019s Remicade, AbbVie\u2019s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options include Takeda\u2019s Entyvio, Pfizer\u2019s Xeljanz, Johnson &#038; Johnson Innovative Medicine\u2019s Stelara, BMS\u2019s Zeposia, and AbbVie\u2019s Rinvoq), as well as the recently launched agents Velsipity (Pfizer), Omvoh (Eli Lilly), Skyrizi ( AbbVie), and Tremfya (Johnson &#038; Johnson Innovative Medicine). Also competing in this market is biosimilar infliximab (e.g., Pfizer\u2019s Inflectra, Merck\u2019s Renflexis). The launch of adalimumab biosimilars (e.g., Amjevita) and the potential arrival of emerging agents\u2014some with novel MOAs (including Abivax\u2019s ABX464, Merck\u2019s MK-7240)\u2014will further fuel competition and add to pricing pressure. This report addresses the market access challenges facing emerging therapies, with insights into securing favorable coverage and uptake.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do MCO restrictions impact physicians\u2019 prescribing of biologics \/ oral targeted agents for UC?<\/li>\n<li>How do MCOs cover branded biologics \/ oral targeted agents in their largest fully insured commercial plans, and which utilization management controls do they use<\/li>\n<li>How do pharmacoeconomic \/ health economic and outcomes research data impact formulary decision-making about therapies for UC?<\/li>\n<li>How do payers expect to cover emerging\/recently approved therapies, including Skyrizi, Tremfya, ABX464, and MK-7240, in their commercial health plans, and how does this coverage align with physicians\u2019 anticipated prescribing of these agents?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW92978545 BCX8 round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. gastroenterologists and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/p>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by commercial plans covering more than 165 million lives nationally and Medicare Part D plans covering up to 37.5 million lives.<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs<\/strong>: Remicade, Humira, biosimilar adalimumab, biosimilar infliximab, Entyvio, Stelara, Xeljanz, Rinvoq, Zeposia, Skyrizi, Tremfya, Omvoh, Velsipity.<\/p>\n","protected":false},"template":"","class_list":["post-483684","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-therapy-areas-ulcerative-colitis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/483684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/483684\/revisions"}],"predecessor-version":[{"id":575767,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/483684\/revisions\/575767"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=483684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}